Form 4: Teladoc Director Granted 53,648 Restricted Stock Units

Teladoc Health Director Michael S. Smith received a grant of 53,648 restricted stock units, aligning his interests with shareholders.

Summary

• Michael S. Smith, a Director of Teladoc Health, Inc. (TDOC), was granted 53,648 Restricted Stock Units (RSUs).
• Each RSU represents a contingent right to receive one share of TDOC common stock.
• The RSUs were granted on February 18, 2026, with a reported transaction price of $0 per unit.
• The vesting schedule for these RSUs is structured such that one-third will vest on the first anniversary of the grant date.
• The remaining two-thirds will vest in eight substantially equal quarterly installments following the initial anniversary.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While not a direct open market purchase, it represents a standard compensation practice that aligns the director's financial interests with the long-term performance of Teladoc Health.

Positives

• The grant of Restricted Stock Units to a director aligns management's long-term interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• This is a standard form of executive and director compensation, indicating continuity in the company's remuneration practices.

Future Outlook

The grant of Restricted Stock Units indicates a future commitment of shares to the director, contingent on continued service and the company's performance, with vesting scheduled over several years.

Industry Context

StockSavvy.ai notes that the grant of Restricted Stock Units (RSUs) is a common and widely accepted form of equity compensation for directors and executives across the healthcare technology sector. This practice aims to incentivize long-term performance and align the interests of leadership with those of shareholders.

Comparison to Industry Standards

• RSU grants are a standard component of director compensation packages in publicly traded companies, particularly within the technology and healthcare sectors, comparable to practices at companies like Amwell (AMWL) or Livongo Health (LVGO, prior to acquisition).
• The vesting schedule, with an initial anniversary vesting followed by quarterly installments, is a common structure designed to promote retention and long-term commitment, similar to equity compensation plans observed at major tech firms.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with shareholder value creation, as the value of the RSUs is directly tied to the company's stock price performance.
• Employees: This filing specifically pertains to a director's compensation and does not directly impact the broader employee base, though it reflects standard equity compensation practices at the leadership level.

Next Steps

• One-third of the granted Restricted Stock Units will vest on the first anniversary of the grant date (February 18, 2027).
• The remaining two-thirds of the RSUs will vest in eight substantially equal quarterly installments thereafter.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a director and does not provide new fundamental information that would warrant a change in investment recommendation. It is a standard event that aligns insider interests with shareholders but does not signal a significant shift in the company's outlook or valuation.

Keywords

Teladoc Health, TDOC, Restricted Stock Units, RSU Grant, Insider Transaction, Director Compensation, Form 4, Equity Compensation